FDA Chides Pfizer For Omitting Drug Risks On Lipitor Website | WAMU 88.5 - American University Radio

NPR : News

Filed Under:

FDA Chides Pfizer For Omitting Drug Risks On Lipitor Website

Somebody who didn't like the way Pfizer was promoting a bunch of its drugs on a website for cholesterol-fighter Lipitor tipped off the Food and Drug Administration about it. And the agency agreed.

In a written reprimand, the agency faulted Pfizer for failing to tell people about risks from Caduet, a pill to treat high cholesterol and blood pressure; Norvasc, for high blood pressure; and Chantix, a pill to help people quit smoking.

The basic problem, according to the FDA, was that links to pages with more information about these drugs featured language describing what the piils do without mentioning any of the risks they pose.

"By omitting the most serious and frequently occurring risks associated with Caduet, Chantix, and Norvasc, the webpage misleadingly suggests that these drugs are safer than have been demonstrated," the FDA wrote.

Pfizer has until Sept. 14 to respond to the agency's letter. In an email to Shots, a Pfizer spokesman said the company "is in the process of reviewing and responding to the FDA letter and has already removed the cited content from the Lipitor website."

The Pfizer letter is just the latest FDA enforcement action spawned by a "bad ads" initiative launched in May 2010. FDA Commissioner Margert Hamburg asked doctors, nurses and pharmacists around the country to become tipster and help root out false and misleading marketing of drugs.

In a report on how things are going, the agency said in the first year it received 328 tips, more than triple the yearly average before the call for help. Most came from health professionals, and 87 of those prompted a careful look by the FDA. For a look at some of the problems that resulted in action, you can find links to five agency letters here.

For all the hoopla, most doctors remain unaware of the tip program, according to a survey highlighted by the blog Pharmalot in March. Speaking of, I was unaware of the latest action against Pfizer until Pharmalot blogged about it this morning.

For more on how the tip program is supposed to work, check out the FDA video.

Copyright 2011 National Public Radio. To see more, visit http://www.npr.org/.

NPR

How'd A Cartoonist Sell His First Drawing? It Only Took 610 Tries

Tom Toro was a directionless 20-something film school dropout. Then, after an inspired moment at a used book sale, he started submitting drawings to The New Yorker ... and collecting rejection slips.
NPR

Will Environmentalists Fall For Faux Fish Made From Plants?

A handful of chefs and food companies are experimenting with fish-like alternatives to seafood. But the market is still a few steps behind plant-based products for meat and dairy.
NPR

Will We See Veto Battles On Capitol Hill?

With President Obama promising to vetoes, what are the possibilities of a few veto overrides during the next two years? NPR's Arun Rath puts that questions to the National Journal's Fawn Johnson.
NPR

3 Voices, 1 Threat: Personal Stories Of Cyberhacking

In President Obama's State of the Union address, he gave fresh emphasis to a problem that has been in the headlines: cybersecurity. Here are three people who have experienced security breaches.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.